One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with…
Articles by Steve Bryson, PhD
Canada’s Drug Agency (CDA-AMC) has recommended that Canadian public drug plans cover the cost of the gynecological cancer therapy…
All three adults with high-risk acute myeloid leukemia (AML) who had already been given 3-4 lines of cancer treatment responded…
The U.S. Food and Drug Administration has approved a new rapid diagnostic test to identify patients with treatment-resistant acute leukemias…
The gynecological cancer therapy Elahere (mirvetuximab soravtansine) is now approved in Canada for adults with platinum-based, chemotherapy-resistant, ovarian, fallopian…
The first patient has been dosed in a Phase 1 clinical trial that’s testing a gene therapy for people with…
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral…
The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in…
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more…
A study found that analyzing levels of immune cells and related molecules in the bloodstream of people with glioma…